Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab or Necitumumab + Osimertinib in T790M+ EGFR-Mutant NSCLC
NCT02789345Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2016
- Primary completion
- Oct 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of ramucirumab and necitumumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Dose Limiting Toxicities at Cycle 2. Started Oct 2016; status: completed.
02
Drugs
ramucirumabnecitumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02789345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02789345.